title: Economic assessment of different modalities of immunoglobulin replacement therapy.
abstract: The delivery (intravenous or subcutaneous), location (home or hospital), and other factors of immunoglobulin replacement therapy are examined for cost effectiveness. Cost-minimization studies from several countries are reviewed and analyzed. A Canadian cost-minimization study is performed. Although common themes emerge, there are cost differences between the various countries.
authors.affiliation: Canadian Agency for Drugs and Technologies in Health (CADTH), 600-865 Carling Avenue, Ottawa, ON, Canada K1S 5S8.
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Membe
authors.forename: Chuong
authors.initials: C
authors.lastname: Ho
authors.forename: Karen
authors.initials: K
authors.lastname: Cimon
authors.forename: Andra
authors.initials: A
authors.lastname: Morrison
authors.forename: Amin
authors.initials: A
authors.lastname: Kanani
authors.forename: Chaim M
authors.initials: CM
authors.lastname: Roifman
mesh_terms: D000328:Adult; D002170:Canada; D002675:Child, Preschool; D003363:Cost Control; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems / Q000191:economics / Q000379:methods; D017048:Health Care Costs; D054625:Healthcare Disparities / Q000191:economics; D006801:Humans; D007116:Immunization, Passive / Q000191:economics* / Q000379:methods; D007153:Immunologic Deficiency Syndromes / Q000191:economics / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic